4 April 2016 EMA/95397/2016 Inspections and Human Medicines Pharmacovigilance

Workshop: measuring the impact of pharmacovigilance activities Call for expressions of interest 5 - 6 December 2016 European Medicines Agency, London, United Kingdom

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 E-mail [email protected] Website www.ema.europa.eu

An agency of the European Union

© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.

Workshop: measuring the impact of pharmacovigilance activities Call for expressions of interest Workshop objectives The workshop will bring together the partners and stakeholders involved in the performance of pharmacovigilance activities or impacted by pharmacovigilance with the following objectives: 1. Review the PRAC approach for measuring the impact of pharmacovigilance activities and regulatory decisions. 2. Identify enablers and barriers to measure the impact of pharmacovigilance activities. 3. Share and develop methodologies for measuring impact of individual product specific pharmacovigilance activities on clinical practice including intermediate indicators and health outcomes. 4. Share and develop methodologies for measuring the impact of the different pharmacovigilance processes. 5. Engage partners and stakeholders in collaborative efforts to measure the impact of pharmacovigilance activities.

Scope EU pharmacovigilance systems have been established to fulfil the tasks and responsibilities of EU pharmacovigilance legislation, to monitor the safety of authorised medicinal products and to detect and manage any change to their risk-benefit balance. Pharmaceutical companies and regulators have access to a variety of post-marketing surveillance tools that allow for systematic monitoring of the benefits and risks of medicinal products throughout the life-cycle. Pharmacovigilance activities include risk management planning and the detection, assessment, evaluation and management of drug-related adverse effects. They are designed to prevent harm caused by medicines and to enable their safe and effective use. In January 2016 the Pharmacovigilance Risk Assessment Committee (PRAC) has adopted a strategy 1 for measuring the impact of pharmacovigilance activities which relies on a collaborative approach between stakeholders. Measuring the impact of key pharmacovigilance activities will allow those responsible for pharmacovigilance to determine which activities are most successful and to identify enablers and barriers for generating positive health impacts. Together, these will contribute to the further development of proactive pharmacovigilance systems and to promote best practice across the EU. The aim of this workshop is to facilitate the implementation of the PRAC strategy through the objectives outlined above, with a particular focus on the development of methodologies and on stakeholder collaboration.

1 Pharmacovigilance Risk Assessment Committee. PRAC strategy on measuring the impact of Pharmacovigilance activities (EMA/790863/2015).

Workshop: measuring the impact of pharmacovigilance activities EMA/95397/2016

Page 2/3

Who the workshop might be of interest to The presentations and discussions will include experts and stakeholders in the following areas: •

Regulatory bodies: EU and national regulatory agencies, international regulatory bodies.



Public bodies: national health authorities, the European Commission, the WHO.



Academia and learned societies, including experts in methodologies.



Healthcare professional organisations' representatives.



Patient and consumer organisations' representatives.



Pharmaceutical industry associations' representatives.

Programme Committee June Raine (PRAC), Tomas Salmonson (CHMP), Peter Bachmann (CMDh), Dirk Mentzer (PDCO), Marieke De Bruin (PRAC), Almath Spooner (PRAC), Dolores Montero (PRAC), Isabelle Moulon (EMA), Michael Berntgen (EMA), Xavier Kurz (EMA), Peter Arlett (EMA).

Call for expression of interest Attendance at this workshop is free; however, due to limited space, pre-registration is required. The Agency will consider expressions of interest to participate and will ensure that there is a reasonable balance of representatives of different partners and stakeholder groups. Should you be interested in attending this workshop, please send an email indicating any particular areas of interest to: [email protected].

Deadline for receipt of requests to participate 30 September 2016.

Media disclaimer The European Medicines Agency records or broadcasts a number of its meetings, including some virtual meetings. This is part of the Agency's commitment to the principle of transparency, as enshrined in the Treaty on the European Union. The Agency herewith informs attendees that this particular meeting will be recorded and/or broadcast. By attending this meeting you consent to any recording or broadcast.

Workshop venue and secretariat European Medicines Agency 30 Churchill Place, Canary Wharf London E14 5EU, United Kingdom Telephone +44 (0)20 3660 6000 E-mail [email protected] Website www.ema.europa.eu

Workshop: measuring the impact of pharmacovigilance activities EMA/95397/2016

Page 3/3

Workshop on measuring impact of ... - European Medicines Agency

Apr 4, 2016 - E-mail [email protected] Website www.ema.europa.eu ... access to a variety of post-marketing surveillance tools that allow for systematic ...

153KB Sizes 19 Downloads 254 Views

Recommend Documents

Adaptive Pathways Workshop Report - European Medicines Agency
Dec 8, 2016 - trial data. > Involve stakeholders, such as HTA bodies, early in the development process .... 'big data') and represent great challenges and.

Agenda - Patient Registries Workshop - European Medicines Agency
Oct 18, 2016 - Send a question via our website www.ema.europa.eu/contact ... marketing authorisation holder (MAH) to create a new registry based on a ...

Agenda - Data anonymisation workshop - European Medicines Agency
Nov 30, 2017 - broader set of data which ensure privacy protection and meet the standards required to maintain ... To understand the legislation impacting clinical data sharing across two jurisdictions, drawing out differences and .... healthcare dat

Workshop summary - European Medicines Agency - Europa EU
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website www.ema.europa.eu/contact. © European Medicines Agency ...

Agenda - Adaptive pathways workshop - European Medicines Agency
Dec 6, 2016 - early access tools. Francesca Cerreta. (EMA). 09.15-. 09.30 ... Methodological challenges and the monitoring advantage of Real World Data.

Agenda - Workshop on single-arm trials - European Medicines Agency
30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the ... Human Medicines Research & Development Support Division.

Agenda - Workshop on single-arm trials - European Medicines Agency
30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the ... Human Medicines Research & Development Support Division.

Workshop summary - European Medicines Agency - Europa EU
Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins. Workshop Summary. 9th March at the European Medicines Agency, ...

Guideline on Influenza Vaccines - European Medicines Agency
Jul 20, 2017 - seed and/or end of production seed) and comparison with the CVV (or publically accessible database ..... The guidance provided in section 4.1.1.1.6 applies. 4.1.2.1.7. ...... SOP xyz. Plasmids HAxx and NAzz used plus six PR8 ...

Notice - European Medicines Agency
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti

Report - European Medicines Agency
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.

Workshop on measuring the impact of pharmacovigilance activities
Mar 23, 2017 - broad consensus that all stakeholders of pharmacovigilance have a ..... The contribution of social media to impact research needs to be further.

Workshop on measuring the impact of pharmacovigilance activities
Nov 25, 2016 - Page 3/14. Welcome to participants ... advanced pharmacovigilance systems in the world and we share a responsibility to ensure that key.

Guideline on Influenza Vaccines - European Medicines Agency
Jul 20, 2017 - Data deriving from multiple strains should be used to develop a .... evaluated by appropriate analytical methods, e.g. Dynamic Light Scattering.

Workshop on measuring the impact of pharmacovigilance activities
Mar 23, 2017 - pharmacovigilance activities to support the EU regulatory network's legal mandate to ... continuous scientific development based on best evidence and health ..... campaign a survey provided baseline understanding of Canadians' ... The

Patient registries workshop - European Medicines Agency - Europa EU
Feb 13, 2017 - Benefits for Health Technology Assessment (HTA) and payers . ..... limitations and to develop the next steps of the EMA Registry initiative.

European Medicines Agency policy on the handling of declarations of ...
Oct 6, 2016 - attendance at accredited courses or conferences with respect to continuing .... public call for expression of interests is launched by the Agency.

Human Medicines Highlights Newsletter - European Medicines Agency
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. • Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. • Feraccru (ferr

Veterinary medicines highlights 2016 - European Medicines Agency
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...

Human Medicines Highlights Newsletter - European Medicines Agency
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...

Human Medicines Highlights Newsletter - European Medicines Agency
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...

Agenda - European Medicines Agency - europa.eu
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...

Patient registries workshop - European Medicines Agency - Europa EU
Feb 13, 2017 - 10. 3.3. Benefits and challenges of collaborations . ..... pharmaceutical companies and 9 from registry holders. Of the eight topics discussed with.

4.1 MS Workshop Report- draft 3 - European Medicines Agency
Oct 9, 2017 - The MS registry landscape in Europe comprises regional and national registries that are broadly affiliated with one of ..... external systems. - Communication to patients to encourage enrolment. Recommendations. •. Raise awareness of